Inclusion Criteria:

- Able to read and write, understand instructions related to trial procedures and give
written informed consent before any trial-related activity is performed

- Histologically confirmed adenocarcinoma of the prostate (prostate cancer)

- Currently under hormonal management of prostate cancer with a GnRH agonist

- Confirmed biochemical PSA progression on GnRH agonist therapy, defined as ≥50%
increase in PSA between 2 measurements, taken at least 1 week apart

- PSA ≥1.0 ng/ml

- ECOG score ≤2

- Able and willing to participate in the full duration of the clinical trial

- Male patient aged 18 years or older

- Life expectancy of at least 12 months

Exclusion Criteria:

- Prior treatment with chemotherapy, radiopharmaceuticals, estrogen, ketoconazole or
other secondary hormonal treatments such as antiandrogens except for induction phase
(<3 months)

- History of dermatitis, lupus, eczema, psoriasis affecting area used for Degarelix
injections

- Allergy to Degarelix or its components

- Has a clinically significant disorder (other than prostate cancer) including, but not
limited to, renal, haematological, gastrointestinal, endocrine, cardiac,
neurological, or psychiatric disease, and alcohol or drug abuse or any other
condition, which may affect the patient's health or the outcome of the trial as
judged by the Investigator

- Has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy.

- Has a history of severe untreated asthma, anaphylactic reactions, or severe urticaria
and/or angioedema

- Has a mental incapacity or language barrier precluding adequate understanding or co
operation